



Fig. S1. The combination of osimertinib with trametinib does not further decrease the survival of NSCLC cells lines with WT EGFR. The indicated cell lines plated in 96-well plates were exposed to the varied concentrations of osimertinib alone, trametinib or or their respective combinations. After 3 days, cell numbers were estimated using the SRB assay. The data are means \pm SDs of four replicate determinations.